Annexon, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANNX Nasdaq 2836 www.annexonbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annexon, Inc.

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Aug 24th, 2026 2:08 am
Annexon (ANNX) Q2 2026 Earnings Call Transcript - Aug 19th, 2026 7:58 am
Annexon (ANNX), What Is Behind Its Latest Update? - Aug 13th, 2026 12:13 pm
Annexon, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 2:56 pm
Annexon Q2 Earnings Call Highlights - Aug 12th, 2026 7:03 am
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts - Aug 12th, 2026 5:33 am
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones - Aug 12th, 2026 4:05 am
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study - Aug 12th, 2026 4:00 am
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors - Aug 10th, 2026 2:05 pm
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week - Aug 6th, 2026 6:00 am
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance - Jul 30th, 2026 2:01 pm
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates - Jul 16th, 2026 5:17 pm
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026 - Jul 14th, 2026 2:05 pm
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Jun 16th, 2026 2:05 pm
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead - Jun 9th, 2026 7:06 am
Exploring 3 High Growth Tech Stocks in the US Market - Jun 9th, 2026 5:38 am
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout - Jun 4th, 2026 1:07 am